$RGNT News

Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon

Regentis Biomaterials Partners With Humanitas Research Hospital In Italy Over Expanding Clinical Activities In Europe

Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%

Regentis Biomaterials Develops New Manufacturing Process For GelrinC, Off-The-Shelf Hydrogel Synchronized Erosion And Resorbable Implant For Treatment Of Painful Injuries To Focal Articular Knee Cartilage

Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update

Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch

Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair

Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs

Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial

Regentis Biomaterials Names Ori Gon Chief Financial Officer And Chief Business Officer, As GelrinC Progresses In US Food and Drug Administration Phase III Trial

Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.

Regentis Biomaterials Shares Halted On Circuit Breaker, Stock Now Down -27.67%

Regentis Biomaterials Shares Halted On Circuit Breaker, Stock Now Down -27.67%

Regentis Biomaterials Shares Halted On Circuit Breaker To The Downside, Stock Now Down -15.04%

Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method

Regentis Biomaterials GelrinC Demonstrates True Hyaline Cartilage Regeneration Two Years Post-Treatment In Long-Term Clinical Trial Data

Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation

Regentis Biomaterials Publishes Data On Phase 2 Clinical Study Of GelrinC

Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC

Regentis Biomaterials Secures Patent For Liquid, Ready-To-Use GerlinC Formulation, Enhancing Efficiency In Knee Cartilage Repair